Treatment with CD8+ T cell-depleting antibodies restored tumor growth in the absence of ADAM12+ cells, confirming that ADAM12+ cells block antitumor activity of CD8+ T cells (Extended Data Fig. 1q). Here, CD8A is linked to neoplasm.